Brochure
28 Mar 2019

Interview by Newsweek, Time to Talk

PDF 272 kB

Interviewee:Dr. Steve J. P. Hsu (President of Genovior Biotech)

Content provided by our supplier

Genovior Biotech Corporation

  • TW
  • 2016
    On CPHI since
  • 1
    Certificates
  • 100 - 249
    Employees
Company types
CMO/CDMO
Primary activities
Contract Manufacturer

Other Content from Genovior Biotech Corporation (2)

  • News Interview by Newsweek, Time to Talk

    An interview with Dr. Steve J.P. Hsu, President of Genovior Biotech.
  • Video COMPANY PRESENTATION

    Genovior is a dedicated CMO/CDMO, focusing on providing clients excellent, efficient, one stop services and solutions, from clinical trials (IND/NDA) to commercialization.

    Our services include:
    1. Process Development
    2. Formulation Development
    3. Analytical Development
    4. Small Scale Biologics / Injectable Production
    5. Commercial Scale Injectable Production

    6. Dedicated Oncology Production (API / Injectables)
    7. Regulatory Affairs

    Generic/Peptide/Biosimilar projects available for out-licensing
    Oncology-Azacitidine, Bortezomib, Pemetrexed, Fulvestrant
    Peptide-Glucagon, Teriparatide, Octreotide, Terlipressin
    Biosimilar-Liraglutide, Ranibizumab, Denosumab
    Others-Levetiracetam, Palonosetron, Valproate